Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209124 | 1.00 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL5971548 | 1.00 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL227362 | 1.00 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL3263816 | 0.94 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1 | |
| SCHEMBL3263812 | 0.94 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1 | |
| SCHEMBL2125181 | 0.94 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1 | |
| SCHEMBL2125184 | 0.94 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1 | |
| SCHEMBL2124624 | 0.93 | CYSLTR2 (0.66) | CYSLTR2CYSLTR1 | |
| SCHEMBL5601096 | 0.89 | CYSLTR1 (0.66) | CYSLTR2CYSLTR1 | |
| SCHEMBL5200473 | 0.85 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | US | claimed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-112279808-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112250627-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-107690281-B | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-106163517-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-110840847-A | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2020-02-28 | — | — | CN | disclosed |
| US-9687617-B2 | Nebulizer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-20140158118-A1 | NEBULIZER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8286632-B2 | Dispensing device | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20080289627-A1 | DISPENSING DEVICE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2002067938-A2 | TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | SCHERING CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | CYSLTR2 655/4885CYSLTR1 457/4885 |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | ABCB1, ABCC4, ABCC1 | CYSLTR2 1023/4885CYSLTR1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.